Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079644 · ClinicalTrials.gov registry record
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 678
- Enrollment target
NCT07079644 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 678 participants.
The verdict
NCT07079644 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 678 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
Interventions
- BIOLOGICAL Nivolumab + Relatlimab
- BIOLOGICAL Nivolumab + Ipilimumab
- BIOLOGICAL Immunotherapy monotherapy
- DRUG BRAF/MEK inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2024-11-29 |
| Est. Completion | 2025-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07079644
The ClinicalTrials.gov registry entry for NCT07079644 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 678 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab + Relatlimab is the first listed.
NCT07079644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07079644 about?
NCT07079644 is a clinical study titled "Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database". The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors the...
What is the current status of trial NCT07079644?
This trial is currently completed. The enrollment target is 678 participants. The study started on 2024-11-29. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT07079644?
The interventions under investigation include: Nivolumab + Relatlimab (BIOLOGICAL), Nivolumab + Ipilimumab (BIOLOGICAL), Immunotherapy monotherapy (BIOLOGICAL), BRAF/MEK inhibitors (DRUG).
Who is sponsoring clinical trial NCT07079644?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.